THE Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee has published the outcomes from its latest meeting in late Sep, reviewing febuxostat, hepatitis C medicines, ruxolitinib and bevacizumab - see pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Nov 18